GSK’s Linerixibat for PBC Pruritus Gains EMA Review Acceptance

An announcement from GlaxoSmithKline ( (GB:GSK) ) is now available.

GSK announced that the European Medicines Agency has accepted the marketing authorisation application for linerixibat, a targeted inhibitor for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC). This follows the FDA’s acceptance earlier, highlighting linerixibat’s potential to address the unmet medical need for effective treatments for PBC-related relentless itch and sleep disruption. The application is based on positive results from the GLISTEN phase III trial, which showed significant improvements in pruritus and sleep interference. If approved, linerixibat could significantly impact GSK’s operations and market positioning by providing a novel treatment option for PBC patients.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.

GlaxoSmithKline shows solid financial performance and positive corporate actions, such as product approvals and share buybacks, which boost confidence. However, the stock faces technical challenges and high debt, tempering the overall score.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GSK is a global biopharma company focused on uniting science, technology, and talent to advance disease treatment. The company is actively researching treatments for various liver diseases, including primary biliary cholangitis (PBC), chronic hepatitis B, alcohol-related liver disease, and metabolic dysfunction-associated steatohepatitis.

Average Trading Volume: 10,173,457

Technical Sentiment Signal: Hold

Current Market Cap: £56.79B

Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.